The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?

被引:138
作者
Qvist, Per [1 ]
Bay-Jensen, Anne-Christine [1 ]
Christiansen, Claus [1 ]
Dam, Erik B. [1 ]
Pastoureau, Philippe [2 ]
Karsdal, Morten A. [1 ]
机构
[1] Nord Biosci AS, DK-2730 Herlev, Denmark
[2] Inst Rech Servier, F-92150 Suresnes, France
关键词
DMOAD; osteoarthritis; treatment;
D O I
10.1016/j.phrs.2008.06.001
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Till date, the pharmaceutical industry has failed to bring effective and safe disease modifying osteoarthritic drugs (DMOADs) to the millions of patients suffering from this serious and deliberating disease. We provide a review of recent data reported on the investigation of DMOADs in clinical trials, including compounds inhibiting matrix-metalloproteinases (MMPs), bisphos phonates, cytokine blockers, calcitonin, inhibitors of inducible nitric oxide synthase (NOS), doxycycline, glucosamine, and diacereine. We discuss the challenges associated with the drug development process in general and with DMOADs in particular, and we advance the need for a new development paradigm for DMOADs. Two central elements in this paradigm are a stronger focus on the biology of the joint and the application of new and more sensitive biomarkers allowing redesign of clinical trials in osteoarthritis. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 65 条
[1]
Biologics in development for rheumatoid arthritis: Relevance to osteoarthritis [J].
Abramson, Steven B. ;
Yazici, Yusuf .
ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (02) :212-225
[2]
[Anonymous], 2007, Drugs R D, V8, P255
[3]
Early postmenopausal hormone therapy may prevent cognitive impairment later in life [J].
Bagger, YZ ;
Tankó, LB ;
Alexandersen, P ;
Qin, GR ;
Christiansen, C .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (01) :12-17
[4]
Effects of calcitonin on subchondral trabecular bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency [J].
Behets, C ;
Williams, JM ;
Chappard, D ;
Devogelaer, JP ;
Manicourt, DH .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (11) :1821-1826
[5]
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee - Results of the two-year multinational knee osteoarthritis structural arthritis study [J].
Bingham, Clifton O., III ;
Buckland-Wright, J. Chris ;
Garnero, Patrick ;
Cohen, Stanley B. ;
DougadoS, Maxime ;
Adarni, Silvano ;
Clauw, Daniel J. ;
Spector, Timothy D. ;
Pelletier, Jean-Pierre ;
Raynauld, Jean-Pierre ;
Strand, Vibeke ;
Simon, Lee S. ;
Meyer, Joan M. ;
Cline, Gary A. ;
Beary, John F. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (11) :3494-3507
[6]
Birmingham JD, 2006, BIOMARK INSIGHTS, V1, P61
[7]
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer [J].
Bissett, D ;
O'Byrne, KJ ;
von Pawel, J ;
Gatzemeier, U ;
Price, A ;
Nicolson, M ;
Mercier, R ;
Mazabel, E ;
Penning, C ;
Zhang, MH ;
Collier, MA ;
Shepherd, FA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :842-849
[8]
A pilot, two-year longitudinal study of the interrelationship between trabecular bone and articular cartilage in the osteoarthritic kneel [J].
Blumenkrantz, G ;
Lindsey, CT ;
Dunn, TC ;
Jin, H ;
Ries, MD ;
Link, TM ;
Steinbach, LS ;
Majumdar, S .
OSTEOARTHRITIS AND CARTILAGE, 2004, 12 (12) :997-1005
[9]
Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs [J].
Brandt, KD ;
Mazzuca, SA .
ARTHRITIS AND RHEUMATISM, 2005, 52 (11) :3349-3359
[10]
Effects of doxycycline on progression of osteoarthritis - Results of a randomized, placebo-controlled, double-blind trial [J].
Brandt, KD ;
Mazzuca, SA ;
Katz, BP ;
Lane, KA ;
Buckwalter, KA ;
Yocum, DE ;
Wolfe, F ;
Schnitzer, TJ ;
Moreland, LW ;
Manzi, S ;
Bradley, JD ;
Sharma, L ;
Oddis, CV ;
Hugenberg, ST ;
Heck, LW .
ARTHRITIS AND RHEUMATISM, 2005, 52 (07) :2015-2025